Order Article Reprints

Mauduit O, Brulard C, Lesluyes T, Delcroix V, Pérot G, Choublier N, Michaud M, Baud J, Lagarde P, Aurias A, et al. RCBTB1 Deletion Is Associated with Metastatic Outcome and Contributes to Docetaxel Resistance in Nontranslocation-Related Pleomorphic Sarcomas. Cancers. 2019; 11(1):81. https://doi.org/10.3390/cancers11010081

Mauduit, Olivier, Céline Brulard, Tom Lesluyes, Vanessa Delcroix, Gaëlle Pérot, Nina Choublier, Mickael Michaud, Jessica Baud, Pauline Lagarde, Alain Aurias, and et al. 2019. "RCBTB1 Deletion Is Associated with Metastatic Outcome and Contributes to Docetaxel Resistance in Nontranslocation-Related Pleomorphic Sarcomas" Cancers 11, no. 1: 81. https://doi.org/10.3390/cancers11010081

Mauduit, O., Brulard, C., Lesluyes, T., Delcroix, V., Pérot, G., Choublier, N., Michaud, M., Baud, J., Lagarde, P., Aurias, A., Coindre, J.-M., Lartigue, L., Blay, J.-Y., & Chibon, F. (2019). RCBTB1 Deletion Is Associated with Metastatic Outcome and Contributes to Docetaxel Resistance in Nontranslocation-Related Pleomorphic Sarcomas. Cancers, 11(1), 81. https://doi.org/10.3390/cancers11010081